AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Growth Differentiation Factor 8, Pipeline Review, H2 2019 - Biogen Inc, PeptiDream Inc, Pfizer & Regeneron Pharmaceuticals Inc - ResearchAndMarkets.com

January 17, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 17, 2020--

The “Growth Differentiation Factor 8 - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

According to the recently published report ‘Growth Differentiation Factor 8 - Pipeline Review, H2 2019’; Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 10 molecules.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

The report ‘Growth Differentiation Factor 8 - Pipeline Review, H2 2019’ outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 3 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Hematological Disorders and Oncology which include indications Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Anemia, Charcot-Marie-Tooth Disease, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuro Muscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) and Thalassemia.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dyoq4p

View source version on businesswire.com:https://www.businesswire.com/news/home/20200117005251/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/17/2020 08:27 AM/DISC: 01/17/2020 08:27 AM

http://www.businesswire.com/news/home/20200117005251/en